Rachel Salazar
Company: Bicara Therapeutics
Job title: Vice President, Head of Programs & Portfolio
Seminars:
BCA101, A Novel Dual-Action Antibody Combining the Precision Targeting of EGFR with the Immunomodulating Power of TGF-β 10:30 am
day: Track B - Day 1 AM